|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 47/69 | (2017.01) |
| A61K 47/64 | (2017.01) | ||
| A61P 31/04 | (2006.01) | ||
| A61K 39/095 | (2006.01) | ||
| A61K 39/015 | (2006.01) | ||
| A61K 39/112 | (2006.01) | ||
| A61P 33/06 | (2006.01) |
| (11) | Number of the document | 3544637 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17816489.3 |
| Date of filing the European patent application | 2017-11-23 | |
| (97) | Date of publication of the European application | 2019-10-02 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-11 |
| (46) | Date of publication of the claims translation | 2021-03-25 |
| (86) | Number | PCT/EP2017/080151 |
| Date | 2017-11-23 |
| (87) | Number | WO 2018/096013 |
| Date | 2018-05-31 |
| (30) | Number | Date | Country code |
| 201619949 | 2016-11-25 | GB | |
| 201712101 | 2017-07-27 | GB |
| (72) |
DI BENEDETTO, Roberta, IT
MICOLI, Francesca, IT
SAUL, Allan James, IT
|
| (73) |
GlaxoSmithKline Biologicals S.A.,
Rue de l`Institut, 89, 1330 Rixensart,
BE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Natyvių OMV ir antigeno konjugatai bei jų naudojimo būdas |
| NATIVE OMV-ANTIGEN CONJUGATES AND USE THEREOF |
| Payment date | Validity (years) | Amount | |
| 2024-10-22 | 8 | 185.00 EUR |
| 2025-11-23 |